Health Sectors Under Pressure: Drug Launch Delays, Merger Moves, and Regulatory Challenges
Published on: April 1, 2026, 2:30 a.m. | Source: Devdiscourse
The health sector is experiencing significant pressure due to the delay in drug launches in Europe related to U.S. pricing policies, mergers, and acquisitions like Eli Lilly's deal with Centessa. Regulatory issues also loom, with FDA rulings affecting the production of certain peptides and a rollback of mercury standards prompting legal action.
